- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2014 (2014), Article ID 491740, 9 pages
Cytotoxicity of Probiotics from Philippine Commercial Dairy Products on Cancer Cells and the Effect on Expression of cfos and cjun Early Apoptotic-Promoting Genes and Interleukin-1β and Tumor Necrosis Factor-α Proinflammatory Cytokine Genes
Biology Department and Center for Natural Sciences and Ecological Research, De La Salle University, 2401 Taft Avenue, 1004 Manila, Philippines
Received 23 February 2014; Revised 26 July 2014; Accepted 30 July 2014; Published 7 September 2014
Academic Editor: Brad Upham
Copyright © 2014 Peter T. Shyu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This study determined cytotoxicity of probiotic Lactobacillus spp. from Philippine dairy products on cancer cells and normal fibroblasts and their effects on expression of early apoptotic-promoting cfos, cjun and proinflammatory cytokine IL-1β, TNF-α genes. Cultures were from Yakult, Bear Brand Probiotic Drink, Nido3+ Powdered Milk. Filter-sterilized supernatants from cultures of Lactobacillus spp. were evaluated for cytotoxicity to colon cancer cells (HT-29 and HCT116), leukemia cells (THP-1), and normal human dermal fibroblasts (HDFn) using PrestoBlue. Bleomycin was the positive control. Absolute quantification of transcript levels was conducted using qRT-PCR. Cytotoxicity index profiles on HDFn, THP-1 of all probiotic supernatants and negative controls suggest nontoxicity to the cells when compared to bleomycin, whereas all probiotic supernatants were found to be cytotoxic to HT-29 and HCT-116 colon cancer cell lines. Expression of cfos, cjun transcripts was significantly upregulated in HT-29 and HCT116 cells treated with probiotic supernatants compared to untreated baseline levels (). Expression of IL-1β and TNF-α by lipopolysaccharide-treated macrophages was significantly downregulated in cells with probiotic supernatants compared to those exposed to MRS medium (). Results provide strong support for the role of Lactobacillus spp. studied in anticancer therapy and in prevention of inflammation that may act as precursor to carcinogenesis.
In recent years, cancer has been reportedly increasing in terms of both incidence and mortality rates in less developed countries, with colon cancer as the third most frequent form of cancer in males and fourth in females [1, 2]. On the other hand, leukemia has been found to compromise immune-competence in patients, further leading to an increased susceptibility to nosocomial bacterial infections, which in turn negatively affects the therapeutic outcome .
Among several other distinct features, cancer cells are characterized by an acquired insensitivity to growth inhibitory signals, as well as to signals that would normally induce apoptosis, or programmed cell death . This may be associated with an alteration in the mitogen-activated protein kinase (MAPK) pathway that regulates the processes of cell division and cell death. The MAPK signal transduction pathway results in the formation of the AP-1 transcription factor, a heterodimer protein composed of the gene products of the cfos and cjun genes. AP-1 has been reported to be involved in cell apoptosis , and it was reported that the activation of the cfos and cjun components of the AP-1 transcription factor increases sensitivity of prostate cancer cells to the tumor necrosis factor related apoptosis inducing ligand (TRAIL) pathway of apoptosis by negative regulation and repression of the antiapoptotic molecule c-FLIP(L) . Several studies have also supported the role of the protein products of cfos and cjun in inducing cell death as a result of cell trauma, exposure to antitumor drug, or withdrawal of survival signals and growth factors [7–11].
Inflammation is a defense mechanism of the body in response to injury caused by infection and harmful stimuli. Immediate resolution of inflammation following infection is termed as acute inflammation and is beneficial for counteracting infection and cell injury . However, failure to resolve inflammation due to changes in the normal immune response may lead to chronic inflammation and alterations in cancer-related genes, which may contribute to tumor formation and metastasis . Some of the effects of inflammation that may contribute to carcinogenesis include causation of genomic instability, epigenetic alterations leading to altered gene expression, enhanced proliferation and invasiveness of cells, and resistance to apoptosis . Moreover, chronic inflammation caused by infections, autoimmune diseases, and infections of uncertain origins have been associated with 25% of cancers worldwide . Tumor Necrosis Factor-α (TNF-α) and Interleukin-1β (IL-1β) are two among the various cytokines produced primarily by activated macrophage cells in response to inflammatory stimuli. Aside from their proinflammatory functions, several studies have also reported increased levels of these cytokines in some types of cancer, thereby providing strong support for their possible roles in cancer progression [15–17].
Recently, a growing number of studies have increasingly shown the various roles of probiotics and have highlighted the many health benefits of the latter. Different microbial species belonging to the genus Lactobacillus have been of particular interest in the development of probiotics. Lactobacillus belongs to a group of Gram-positive, heterotrophic, nonmotile, and nonsporulating bacteria known as lactic acid bacteria (LABs), which are characterized by their production of lactic acid. Aside from being associated with the gastrointestinal tract, LABs are also known as additives to various food products, such as milk and meat products. More notably, several studies have reported on the role of LABs, specifically those belonging to the genus Lactobacillus, against carcinogenesis. Some species that have been identified to be anticancer agents include Lactobacillus rhamnosus, L. casei, L. bulgaricus, and L. acidophilus [18, 19].
However, despite the increasing works of literature on the promising effects of the Lactobacillus spp. against carcinogenesis, majority of the studies conducted have placed their focus only on colon carcinoma cells. Little is known about their effect on leukemia. Moreover, the mechanisms by which Lactobacillus spp. induce cytotoxicity on cancer cells and their role in the induction of anti-inflammatory responses have not been fully understood, despite the many studies that support the relationship between the latter and cancer formation [18, 20, 21].
This study aimed to provide information on potential mechanisms by which probiotic Lactobacillus spp. can induce selective cytotoxic, proapoptotic effects on colon and leukemia cancer cell lines, as well as anti-inflammatory effects on macrophage cells at the molecular level. Furthermore, since conventional methods of cancer treatment are known to cause nonspecific cytotoxic effects on human cells, as well as several other adverse effects on the health of cancer patients, the study aimed to contribute to the development of alternative methods of cancer therapy utilizing probiotic Lactobacillus spp. currently available and accessible to the general public in dairy products, which would yield the same, if not greater, potency of treatment without the risk of compounded health problems. Given the growing body of evidence that associates inflammation with carcinogenesis, this study also aimed to contribute to the development of anti-inflammatory agents that would aid in the prevention of the latter.
2. Materials and Methods
Lactobacillus spp. were previously isolated by Shi  from three commercially available milk products, namely, Yakult, Nido 3+, and Bear Brand (see Figures 1 and 2). Colon cancer cell line HT-29, leukemia cell line THP-1, and normal fibroblast HDFn were generously provided by the Center for Natural Science and Ecological Research (CENSER) of De La Salle University, Manila, Philippines. The colon cancer cell line HCT 116 is a kind gift from Dr. Sonia D. Jacinto of the Institute of Biology, University of the Philippines-Diliman. All cell lines were cultured in 50 mL T-flasks (Falcon, USA), and all incubation processes were done under the following conditions: 5% CO2 with 95% humidity at 37°C.
Bacterial isolates from the three dairy product sources were grown in deMan, Rogosa, and Sharpe (MRS) broth at 37°C with 5% CO2 for 48 hours. The optical densities of the resulting bacterial cultures were adjusted to correspond to of 1.03 (3 × 108 CFU/mL) [19, 23], and the tubes were centrifuged at 13,000 rpm for 3 minutes. The clear supernatant of each culture was carefully obtained and filter-sterilized using a 0.45 μm syringe filter (Millipore, USA) and was used to test for cytotoxicity. The pH of the cell-free supernatants and the uninoculated MRS broth that was used as the negative control were also determined.
HT-29, HCT116, and HDFn (Invitrogen, USA) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, USA) with the addition of 10% fetal bovine serum or FBS (Gibco, USA) and 1x antimycotic antibiotic (Gibco, USA) as a monolayer. HT-29, HCT116, and HDFn were independently harvested with 0.05% trypsin-EDTA in phosphate-buffered saline (PBS; pH 7.4). THP-1 cells were cultured in Roswell Park Memorial Institute or RPMI (Gibco, USA) medium supplemented with 10% FBS, 1x antimycotic antibiotic.
2.1. Cell Viability Assay
All cell lines were cultured to 90% confluence, harvested, and separately seeded in 100 μL volume per well in a 96-well culture plate (Corning, USA). Each 100 μL inoculum had a density of 2.4 × 105 viable cells mL−1 as determined using the Trypan Blue Exclusion method. The plates were incubated for six (6) days. After attachment of cells to the bottom of the wells as monolayers, 100 μLs of twofold dilutions of each of the three (3) prepared filter-sterilized culture supernatants and the MRS broth were added into each well. Twofold serial dilutions of the anticancer drug bleomycin (1 U/mL) were used as the positive control, and DMEM broth with 10% FBS for the untreated setup served as the negative control. All five (5) treatments were done in triplicate, and the plates were incubated for 72 hours.
After incubation, 10 μL of PrestoBlue (Invitrogen, USA) was added to each well. The plates were incubated for another four (4) hours. A microplate reader (BioTek ELx800, BioTek Instruments, USA) was used for colorimetric detection of the reduction of resazurin to resorufin through absorbance measurements taken at 570 nm. The resulting cytotoxicity index values were subsequently plotted against the concentration of the different probiotic supernatants to obtain the corresponding linear equations for the calculation of the minimum inhibitory concentration (IC50) for each probiotic supernatant.
2.2. cfos and cjun Transcript qRT-PCR Assay for Early Apoptosis
HT-29 and HCT116 cells, to which the probiotic supernatants demonstrated cytotoxicity, were further tested for the expression of the early apoptosis genes, cfos and cjun, as follows.
One hundred μL of HT-29 and HCT116 cells (2.4 × 105 cells/mL) was separately seeded into 96-well plates and incubated for 24 hours. After attachment of the cells as monolayers, volumes corresponding to the IC50 of the three probiotic supernatants and of bleomycin were added into each well. Bleomycin was used as the positive control, while the negative control included only cancer cells and cancer cells treated with MRS broth. Each setup was done in duplicate. After 30 minutes of treatment exposure, total RNA was extracted from the cells using the TriZol Reagent (Invitrogen, USA).
All qRT-PCR reactions were carried out using the Rotor-Gene 3000 thermocycler in a final volume of 10 μL solution containing 1 μL of the RNA template, 5 μL of 2x KAPA FAST SYBR (KAPA Biosystems, USA), 0.3 μL each of the 10 μM forward and reverse primers for both cfos and cjun, and 3.4 μL of Diethylpyrocarbonate- (DEPC-) treated water (Invitrogen, USA). The primer sequences are as follows: F: 5′- AAGGAGAATCCGAAGGGAAAGGAATAAGATGGCT-3′, R: 5′-AGACGAAGGAAGACGTGTAAGCAGTGCAGCT-3′ for cfos, and F: 5′-GCATGAGGAACCGCATTGCCGCCTCCAAGT-3′, R: 5′-GCGACCAAGTCCTTCCCACTCGTGCACACT-3′ for cjun .
Initial cDNA synthesis step was done at 50°C for 3 minutes, followed by cDNA amplification consisting of 40 cycles of 95°C for 20 seconds, 55°C for 30 seconds, and 72°C for 35 seconds. Melting analysis was done from 72 to 95°C.
Quantification of amplified transcript levels was done with respect to the simultaneously amplified human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) internal standard concentrations of different known magnitudes, namely, 109, 108, 107, 106, and 105 copies. This was done through the use of the Rotor-Gene 3000 software ver. 6.1.93, which plots a standard curve from which critical threshold (Ct) values were derived.
2.3. IL1-β and TNF-α Transcript qRT-PCR Assay for Anti-Inflammatory Activity
The anti-inflammatory assay of the culture supernatants was adapted from Majlesi  with modifications and was conducted on THP-1 cells. A volume of 100 μL of THP-1 cells (2.4 × 105 cells/mL) was seeded into the wells of a 96-well culture plate, added with 2 μL of phorbol myristate acetate (PMA) (Sigma Aldrich, USA), and incubated for 48 hours to induce differentiation into macrophages. One hundred microliters of 100 ng/mL lipopolysaccharide or LPS (Sigma Aldrich, USA) was then added, and the plates were incubated for one hour. The subsequent experimental setup done is described as follows.
The six (6) negative controls consisted of wells containing 100 μL with 2.4 × 105 cells/mL of THP-1 or PMA-treated THP-1 cells. These are as follows: (1) THP-1 cells cultured to 90% confluence in DMEM medium with 10% FBS, (2) PMA-induced THP-1 cells, (3) PMA-induced THP-1 cells and MRS broth used in the preparation of probiotic cultures, and (4–6) PMA-induced THP-1 cells and the volume of the spent probiotic media corresponding to their respective IC40 values.
The positive control consisted of PMA-induced THP-1 cells added with 100 μL of 100 ng/mL LPS after their differentiation into macrophages . The treatment setup consisted of THP-1 cells treated with PMA, LPS, and volumes of culture supernatants corresponding to IC40 values.
Plates were incubated for one (1) hour after the addition of LPS before administration of the probiotic treatments. All setups were done in duplicate. Incubation time was 30 minutes before the addition of 30 μL RNA Later reagent (Invitrogen, USA) to preserve the RNA integrity of the samples prior to RNA extraction using the TriZol Reagent.
All qRT-PCR reactions were done using the Rotor-Gene 3000 thermocycler in a final volume of 10 μL solution containing 1 μL of the RNA template, 5 μL of 2x KAPA FAST SYBR (KAPA Biosystems, USA), 0.3 μL each of the 10 μM forward and reverse primers for IL1-β and TNF-α, and 3.4 μL of Diethylpyrocarbonate- (DEPC-) treated water (Invitrogen, USA). The primer sequences are as follows: F: 5′-ATGAAGTGCTCCTTCCAGGACCTG-3′, R: 5′-CCTGGAGTGGAGAGCTTCAGTT-3′ for IL-1β, and F: 5′-GGACGTGGAGCTGGCCGAGG-3′, R: 5′-TGGGAGTAGATGAGGTACAGGCCC-3′ for TNF-α .
PCR conditions were as follows: initial cDNA synthesis was done at 50°C for 3 minutes, followed by cDNA amplification consisting of 40 cycles at 95°C for 20 seconds, 50°C for 40 seconds, and 72°C for 20 seconds. Completion of the profile was done by melting from 72 to 95°C using the Corbett RG-3000. Quantification of amplified transcripts was done with reference to established 5-magnitude concentrations of human GAPDH cDNA internal standard.
2.4. Statistical Analysis
Significant differences between the different treatments are determined using Student’s Paired -test performed on Microsoft Excel. A probability value of was designated as the reference value to indicate a statistical difference between treatment results.
3. Results and Discussion
The cytotoxicity of the probiotic supernatants on the four cell lines based on the cell viability assay is shown in Figures 3 and 4. Based on the obtained cytotoxicity index (CI%) plots, the IC50 of the anticancer drug bleomycin was shown to be 9.31% for HDFn and 4.77% for THP-1 cells. No significant cytotoxic activity was observed with the spent media supernatants of all Lactobacillus spp. and the MRS broth medium on both HDFn and THP-1 cell lines as there was no identifiable probiotic treatment concentration that would inhibit at least 50% of the total number of cells (i.e., no IC50 value was determined) (Figures 3(a)-3(b)).
Conversely, all probiotic supernatant treatments showed significant and specific cytotoxicity against the HT-29 and HCT116 cell lines, which was similar to that of bleomycin (Figures 3(c)-3(d)). It could be noted that the Bear Brand treatment group had a higher cytotoxicity for HT-29 cells (IC50 = 7.86%) compared to that of bleomycin (IC50 = 11.49%) (Figure 4(a)), while the Nido treatment had a higher cytotoxicity (IC50 = 8.47%) compared to bleomycin (IC50 = 11.34%) for HCT116 cells (Figure 4(b)). However, no significant difference was found between the two groups for either cell line (). The same is true between bleomycin and the other two probiotic treatment groups for both HT-29 and HCT116 cells.
The expression of the early apoptosis marker gene cfos was significantly increased in HT-29 cells treated with Bear Brand (), Nido (), and Yakult () probiotic supernatants (Figure 5(a)) compared to the untreated negative control and cells treated with MRS broth. The same trend was observed for the expression of cjun, which was also significantly increased in the Bear Brand (), Nido (), and Yakult () treatment groups (Figure 5(b)). A significant increase in the expression of both cfos and cjun was also observed for HCT116 cells treated with the three probiotic supernatants () (Figures 6(a)-6(b)).
Macrophages differentiated from THP-1 cells after exposure to the bacterial antigen LPS were used to evaluate IL1-β and TNF-α expression (Figure 7). Figure 8 shows the downregulation of the expression of both proinflammatory cytokine genes. The downregulation in cells exposed to any of the three probiotic supernatants was significantly different compared to the positive control setup comprised of macrophages exposed to LPS alone (for IL1-β, in all probiotic treatment groups; for TNF-α, in all probiotic treatment groups). No significant difference was found between the positive control and LPS-induced macrophages administered with the MRS culture broth (Figure 8).
The present study assayed the filter-sterilized supernatant from the probiotic cultures to determine whether Lactobacillus spp. from dairy products produce and secrete metabolites with cytotoxic and anti-inflammatory effects. The results showed that all three probiotic supernatants generally follow the same trend with regard to their cytotoxic, proapoptotic, and anti-inflammatory effects. The results of the study strongly suggest that the increased cytotoxicity for HT-29 and HCT116 cells (Figures 3(c)-3(d)) may be associated with a molecular pathway involving an upregulation of the early apoptosis gene markers cfos and cjun. Although studies have reported on the apoptotic effects of different Lactobacillus species on certain cancer cells [18, 19], not much emphasis was placed on the molecular aspect of apoptosis signaling mechanisms, specifically in relation to the aforementioned genes.
The pH values of the three (3) filter-sterilized supernatants were found to be 6.23, 6.35, and 6.37 for Yakult, Nido3+, and Bear Brand, respectively, which were not much more acidic than the uninoculated MRS broth with pH of 6.5 that was used as the negative control. Thus, it can be said that the consequent upregulation of both cfos and cjun after exposure to the probiotic supernatants was not due to stresses brought about by very low extracellular pH. The apoptotic effects of the probiotic supernatants may be mediated either by the formation of the AP-1 transcription factor that activates the MAPK pathway to induce cell death, or by increasing the susceptibility of the cancer cells to the TRAIL-induced apoptosis [6, 29].
From the experimental results, it was also observed that there was a significant decrease in the expression of both proinflammatory cytokine genes, IL1-β and TNF-α, following exposure of LPS-treated PMA-differentiated macrophages to the different probiotic supernatants. Lactobacillus species have been known to secrete metabolites that attenuate the production of the aforementioned cytokines in macrophages induced with the endotoxin in LPS [30, 31].
Anti-inflammatory effects of certain species of Lactobacillus, including L. johnsonii and L. casei, have been evaluated and subsequently confirmed through a reduction in the levels of T-cell-derived proinflammatory cytokine levels, including those of IL-1β and TNF-αamong many others, while concomitantly increasing the levels of the anti-inflammatory cytokines IL-4 and IL-10 in response to inflammatory agents, such as lipopolysaccharide (LPS) and Type II collagen [32, 33]. Moreover, since the anti-inflammatory effect of the treatments was determined in terms of a significant decrease in the number of mRNA copies, the said effect on cytokine production may be narrowed down directly to the transcriptional level, specifically the nuclear factor kappa enhancer binding protein (NF-κB) pathway. This may be a consequence of certain factors present in the supernatant that potentially caused the inhibition of the NF-κB transcription factor itself or the inhibition of the ubiquitin protein, which is necessary for signaling the eventual activation of the NF-κB transcription factor . These ultimately lead to the prevention of the pathway from producing mRNA transcripts of the cytokine genes.
The results of the study showed that spent probiotic culture media from Lactobacillus spp. isolated from Bear Brand, Nido, and Yakult did not have a significant cytotoxic effect on normal HDFn and THP-1 leukemia cells but were significantly cytotoxic for the HT-29 and HCT116 colon cancer cell lines, as evidenced by their respective IC50 values. The cytotoxic activity may be due to the demonstrated upregulation of the early apoptotic gene markers, cfos and cjun, which was significantly higher than in the negative control (). Furthermore, the spent probiotic culture media also exhibited anti-inflammatory effects on LPS-induced macrophage cells, as evidenced by the significant downregulation of the proinflammatory cytokine genes, IL1-β and TNF-α (). This is likely achieved through the inhibition of the NF-κB pathway. These results provide strong support for the role of probiotic Lactobacillus spp. in cancer treatment and prevention of inflammation as a precursor to carcinogenesis.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The authors gratefully acknowledge the Center for Natural Sciences and Ecological Research of the De La Salle University, Manila, Philippines, for the HT 29, THP-1, and HDFn cell lines and for the use of the laboratory facilities and equipment and Dr. Sonia D. Jacinto of the Institute of Biology, University of the Philippines-Diliman, for the HCT-116 cell line.
- A. Jemal, M. M. Center, C. DeSantis, and E. M. Ward, “Global patterns of cancer incidence and mortality rates and trends,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 8, pp. 1893–1907, 2010.
- S. A. Ruste and C. Ngelangel, “QoL of colorectal cancer stoma patients at the Philippine general Hospital—cancer institute,” Phillippine Journal of Internal Medicine, vol. 49, no. 1, pp. 38–42, 2011.
- M. T. Alcala-Chua, “Infections in acute leukemia,” Philippine Journal of Microbiology and Infectious Diseases, vol. 24, no. 1, pp. 22–27, 1995.
- D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000.
- S. Roffler-Tarlov, J. J. G. Brown, E. Tarlov et al., “Programmed cell death in the absence of c-fos and c-jun,” Development, vol. 122, no. 1, pp. 1–9, 1996.
- W. Li, X. Zhang, and A. F. Olumi, “MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L),” Cancer Research, vol. 67, no. 5, pp. 2247–2255, 2007.
- G. A. Preston, D. Srinivasan, and J. C. Barrett, “Apoptotic response to growth factor deprivation involves cooperative interactions between c-Fos and p300,” Cell Death & Differentiation, vol. 7, no. 2, pp. 215–226, 2000.
- J. Galea, J. Armstrong, S. E. Francis, G. Cooper, D. C. Crossman, and C. M. Holt, “Alterations in c-fos expression, cell proliferation and apoptosis in pressure distended human saphenous vein,” Cardiovascular Research, vol. 44, no. 2, pp. 436–448, 1999.
- A. Watson, A. Eilers, D. Lallemand, J. Kyriakis, L. L. Rubin, and J. Ham, “Phosphorylation of c-jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons,” The Journal of Neuroscience, vol. 18, no. 2, pp. 751–762, 1998.
- E. Bossy-Wetzel, L. Bakiri, and M. Yaniv, “Induction of apoptosis by the transcription factor c-Jun,” The EMBO Journal, vol. 16, no. 7, pp. 1695–1709, 1997.
- K. Podar, M. S. Raab, G. Tonon et al., “Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma,” Cancer Research, vol. 67, no. 4, pp. 1680–1688, 2007.
- J. K. Kundu and Y. J. Surh, “Emerging avenues linking inflammation and cancer,” Free Radical Biology and Medicine, vol. 52, no. 9, pp. 2013–2037, 2012.
- N. Eiró and F. Vizoso, “Inflammation and cancer,” World Journal of Gastrointestinal Surgery, vol. 4, no. 3, pp. 62–72, 2012.
- C. Porta, E. Riboldi, and A. Sica, “Mechanisms linking pathogens-associated inflammation and cancer,” Cancer Letters, vol. 305, no. 2, pp. 250–262, 2011.
- F. R. Balkwill and A. Mantovani, “Cancer-related inflammation: common themes and therapeutic opportunities,” Seminars in Cancer Biology, vol. 22, no. 1, pp. 33–40, 2012.
- R. Partanen, H. Koskinen, and K. Hemminki, “Tumour necrosis factor-α (TNF-α) in patients who have asbestosis and develop cancer,” Occupational and Environmental Medicine, vol. 52, no. 5, pp. 316–319, 1995.
- A. M. Lewis, S. Varghese, H. Xu, and H. R. Alexander, “Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment,” Journal of Translational Medicine, vol. 4, article 48, 2006.
- S. S. Choi, Y. Kim, K. S. Han, S. You, S. Oh, and S. H. Kim, “Effects of Lactobacillus strains on cancer cell proliferation and oxidative stress in vitro,” Letters in Applied Microbiology, vol. 42, no. 5, pp. 452–458, 2006.
- J. Yong, Lactobacillus in cancer therapy [M.S. thesis], Singapore, National University of Singapore, 2005.
- M. G. Borrello, D. Degl'Innocenti, and M. A. Pierotti, “Inflammation and cancer: the oncogene-driven connection,” Cancer Letters, vol. 267, no. 2, pp. 262–270, 2008.
- A. Sica, P. Allavena, and A. Mantovani, “Cancer related inflammation: the macrophage connection,” Cancer Letters, vol. 267, no. 2, pp. 204–215, 2008.
- K. Shi, Screening of lactic acid bacteria isolated from commercial dairy products for toxicity to colon cancer cells, leukemia cells and normal fibroblast cells [thesis], De La Salle University, Manila, Philippines, 2012.
- M. C. Mercado and E. Cabrera, “Probiotics from Philippine dairy products are bactericidal for pathogens with transferable multiple drug resistance,” Philippine Science Letters, vol. 4, no. 2, pp. 91–97, 2011.
- A. Rezaei, G. G. Oyong, V. B. Borja et al., “Molecular screening of anti-quorum sensing capability of Salvadora persica on Enterococcus faecalis,” Journal of Hard Tissue Biology, vol. 20, no. 2, pp. 115–124, 2011.
- G. Oyong, M. C. Tan, N. Jafari, M. Aghamohammadian, M. Goodarzi, and M. Noel, “Threonine-serine protein kinase B-mediated cytoprotection by white radish (Raphanus sativus Linn.) aqueous extract on lidocaine -induced neonatal fibroblast injury in vitro,” Journal of the Iranian Chemistry Society, vol. 9, pp. A28–A29, 2012.
- F. M. Huang, M. Y. Chou, and Y. C. Chang, “Dentin bonding agents induce c-fos and c-jun protooncogenes expression in human gingival fibroblasts,” Biomaterials, vol. 24, no. 1, pp. 157–163, 2003.
- I. Majlesi, Inhibition of quorum-sensing controlled virulence factor expression in Streptococcus mutans by Berberis vulgaris L. var. Asperma and molecular screening of its anti-inflammatory potential [M.S. thesis], University of the East, Manila, Philippines, 2012.
- J. W. Tjiu, J. S. Chen, C. T. Shun et al., “Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction,” Journal of Investigative Dermatology, vol. 129, no. 4, pp. 1016–1025, 2009.
- D. Kwon and I.-H. Choi, “Hydrogen peroxide upregulates TNF-related apoptosis-inducing ligand (TRAIL) expression in human astroglial cells, and augments apoptosis of T cells,” Yonsei Medical Journal, vol. 47, no. 4, pp. 551–557, 2006.
- J. A. Peña and J. Versalovic, “Lactobacillus rhamnosus GG decreases TNF-α production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism,” Cellular Microbiology, vol. 5, no. 4, pp. 277–285, 2003.
- S. Pathmakanthan, C. K. F. Li, J. Cowie, and C. J. Hawkey, “Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon,” Journal of Gastroenterology and Hepatology, vol. 19, no. 2, pp. 166–173, 2004.
- J. S. So, M. K. Song, H. K. Kwon et al., “Lactobacillus casei enhances type II collagen/glucosamine-mediated suppression of inflammatory responses in experimental osteoarthritis,” Life Sciences, vol. 88, no. 7-8, pp. 358–366, 2011.
- H.-M. Joo, Y.-J. Hyun, K.-S. Myoung et al., “Lactobacillus johnsonii HY7042 ameliorates Gardnerella vaginalis-induced vaginosis by killing Gardnerella vaginalis and inhibiting NF-κB activation,” International Immunopharmacology, vol. 11, no. 11, pp. 1758–1765, 2011.
- Z. J. Chen, “Ubiquitin signalling in the NF-κB pathway,” Nature Cell Biology, vol. 7, no. 8, pp. 758–765, 2005.